Detecting What
Others Miss.
Early cancer detection powered by optical science & AI.
per year globally
sensitivity
internal validation datasets
About
Qsingula
Qsingula is a next-generation health technology company developing a blood-based diagnostic platform for early cancer detection. Our approach integrates advanced optical science with artificial intelligence to identify biological patterns associated with disease enabling detection at stages where intervention is most effective. We are building a future where cancer is detected earlier, faster, and more accessibly.
Cancer is not just a
treatment challenge.
It is a detection challenge.
Each year:
-
Millions of lives are lost each year due to late diagnosis
-
Most cancers are identified at advanced stages, limiting treatment effectiveness
-
Early-stage detection can increase survival outcomes by up to 5–10 times
-
Early detection also supports proactive health management and longevity strategies
The QSD Test.
Qsingula Platform: A blood draw. A powerful diagnostic insight.
The QSD (Qsingula Screening Diagnostic) platform is designed to detect cancer's signature through a blood sample.
How it works: Blood → Measurement → AI enabled Analysis → Result
Steps to Result
-
CollectA standard liquid biopsy performed at an accredited laboratory.
-
Advanced AnalysisOptical technologies capture biological signals from the sample.
-
EvaluateMachine learning models analyse patterns associated with disease.
-
Always LearningWith every test, our model improves. The platform continuously learns from accumulated data, improving accuracy.
Actionable result supporting clinical decision-making
Detailed methodologies and algorithms are proprietary and protected.
At the intersection of science and medicine
Qsingula combines three major domains:
What Makes Us Different
Our ambition is to build a new paradigm for cancer screening.
Less Invasive
- Only a liquid biopsy is needed (No surgery, no radiation).
- No complex equipment at the point of collection.
- Accessible to virtually anyone.
Data-Driven
- Continuously improving through clinical validation and real-world data
Cost-Conscious
- Built with long-term accessibility in mind
Scalable
- Designed for deployment across healthcare systems globally
Multi-Cancer Potential
- Platform architecture supports expansion across multiple cancer types
Patented & Protected
- Tech-protected knowhow and patents
- Positioned for the global diagnostics market
To enable early detection of cancer through scalable, science-driven diagnostic solutions.
A world where routine blood-based screening becomes a cornerstone of preventive healthcare.
A world where no cancer goes undetected, via a non-invasive, accessible test.
Science First
Every decision we make is grounded in rigorous science, peer-reviewed research, and clinical validation.
Patient at the Centre
Technology is a means to an end. The end is saving lives.
Accessibility
Our technology is scalable and accessible — designed to reach patients everywhere, not just in centres of privilege.
Open Collaboration
We partner with leading universities, hospitals, and research institutions worldwide to accelerate progress.
R&D & Innovation: Conducted over 8 years of research and development, including:
Conducted over eight years of rigorous multidisciplinary research, including:
- Multidisciplinary scientific collaborations
- Clinical research programmes
- Development of proprietary analytical frameworks
- Preparation for regulatory pathways
EU Hub in Italy
Qsingula is establishing its European headquarters in Italy. This strategic location enables:
- Collaboration with leading universities
- Access to EU innovation programmes
- Development of a centre of excellence in AI diagnostics
We aim to contribute to Europe's leadership in deep-tech healthcare innovation.
We are working to establish our middle east Hub in KSA.
Development Status
- Phase III programme initiated in Europe
- Multi-site validation in progress
- Expansion roadmap across multiple cancer types
- Regulatory pathway preparation (CE / FDA alignment)
A rare convergence of oncology, physics, AI and international business expertise.
Qsingula was founded and is led by a team with a combined track record spanning cancer research, operations, and global business development.
- Medicine & Oncology
- Physics & Engineering
- Artificial Intelligence
- Clinical Research & Development
- International Research Programmes
- Healthcare Innovation
- Global Partnerships
The Journey Has Begun.
Partnerships
We are collaborating and actively seeking to expand with:
- Hospitals & Clinical Centres
- Universities & Research Institutions
- Industry & Diagnostic Laboratories
Intellectual Property
Qsingula operates within a structured IP framework including:
- Licensed Technologies
- Proprietary Developments
- Ongoing Innovation
Regulatory & Ethics
We are committed to:
- European & International Regulatory Standards
- Ethical Clinical Research Practices
- Data Protection (GDPR Compliant)
Cancer remains one of the greatest global health challenges of our time. Behind every statistic are lives, families, and futures at stake.
At Qsingula, we are working to enable earlier, more accessible detection with the ambition to transform outcomes through innovation. Progress at this scale is not achieved alone, it is made possible through the support of individuals, institutions, and partners who believe in advancing science for the public good.
We are not predicting the future of cancer detection.
We are
building it.